Tumor cell (iodine-131 targeted)

Tumor cells via beta radiation from iodine-131" refers to malignant cells, most often differentiated thyroid cells and iodine-avid metastases, that are selectively targeted and destroyed by the cytotoxic beta particles emitted from radioactive iodine-131. The specificity of this therapy depends on cellular mechanisms for iodine uptake (primarily the sodium-iodide symporter), allowing internalization of the radiopharmaceutical and subsequent local DNA damage through beta emission. This approach is most established in differentiated thyroid cancers and is also utilized for certain neuroendocrine tumors using radiolabeled MIBG. Not a single molecular target, this therapeutic effect exploits unique physiological uptake pathways to deliver targeted radiation to cancer cells while minimizing effects on normal tissues, though several safety concerns and potential side effects exist due to the radioactive nature of the treatment[3][5][7][1][2][9].

Other names

Tumor cell (radioiodine-avid)Iodine-131-avid tumor cellThyroid cancer cell (for thyroid-specific context)

Selective uptake of radioactive iodine-131 by tumor cells (primarily via sodium-iodide symporter for thyroid-derived malignancies). Beta (\( \beta \)) radiation from iodine-131 induces DNA damage (single- and double-strand breaks). Induction of apoptosis and cell cycle arrest leading to cell death.